Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis
Abstract Objectives Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there are scant data on actual costs and cost-effectiveness in the real world. The aim was to assess the medical costs and outcomes of patients with advanced lung cancer. Methods We retrospecti...
Gespeichert in:
| Veröffentlicht in: | Japanese journal of clinical oncology 2021-05, Vol.51 (5), p.778-785 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 785 |
|---|---|
| container_issue | 5 |
| container_start_page | 778 |
| container_title | Japanese journal of clinical oncology |
| container_volume | 51 |
| creator | Awano, Nobuyasu Izumo, Takehiro Inomata, Minoru Kuse, Naoyuki Tone, Mari Takada, Kohei Muto, Yutaka Fujimoto, Kazushi Kimura, Hitomi Miyamoto, Shingo Igarashi, Ataru Kunitoh, Hideo |
| description | Abstract
Objectives
Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there are scant data on actual costs and cost-effectiveness in the real world. The aim was to assess the medical costs and outcomes of patients with advanced lung cancer.
Methods
We retrospectively investigated all patients who were diagnosed with advanced lung cancer at the Japanese Red Cross Medical Center between 1 January 2008 and 31 December 2018. Patients were classified into three cohorts according to the year of diagnosis—Cohort 1: 2008–2010, Cohort 2: 2011–2014 and Cohort 3: 2015–2018—and assessed for medical costs and outcome. Medical costs were divided into outpatient and inpatient costs and were calculated on a monthly basis.
Results
Ninety-five patients with small cell lung cancer (SCLC) and 330 with nonsmall cell lung cancer (NSCLC) were included. There was a trend toward increased costs during the first two years after diagnosis in NSCLC patients, without changes in monthly costs, reflecting improved survival. Compared to Cohort 1, Cohort 3 patients with NSCLC had longer survival (median: 24 versus 12 months, P |
| doi_str_mv | 10.1093/jjco/hyaa258 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2482663969</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jjco/hyaa258</oup_id><sourcerecordid>2482663969</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-280225b8a958976968e231ecaf50f5f87d71622db1ac721a77d1cf359110f3393</originalsourceid><addsrcrecordid>eNp9kLtOwzAUQC0EolDYmJE3GAj1I3acEVU8VcQCc-T60bpK7WA7Qv17UrUgJqZ7pXvuGQ4AFxjdYlTTyWqlwmS5kZIwcQBOcMlZQTnBh3_2EThNaYUQYqKsjsGIUoY4KesToF-Ndkq2UIWUEwwWtr1fQCW9MnEY0UDn4YvspIe6j2645aWB1sWUYfAGhgjzV4AbI2OC0ubhy3mX3aDUTi58SC6dgSMr22TO93MMPh7u36dPxezt8Xl6NytUyXAuiECEsLmQNRN1xWsuDKHYKGkZssyKSleYE6LnWKqKYFlVGitLWY0xspTWdAyud94uhs_epNysXVKmbaU3oU8NKQXhnNZ8i97sUBVDStHYpotuLeOmwajZdm22XZt91wG_3Jv7-droX_gn5ABc7YDQd_-rvgERRIHr</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2482663969</pqid></control><display><type>article</type><title>Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Awano, Nobuyasu ; Izumo, Takehiro ; Inomata, Minoru ; Kuse, Naoyuki ; Tone, Mari ; Takada, Kohei ; Muto, Yutaka ; Fujimoto, Kazushi ; Kimura, Hitomi ; Miyamoto, Shingo ; Igarashi, Ataru ; Kunitoh, Hideo</creator><creatorcontrib>Awano, Nobuyasu ; Izumo, Takehiro ; Inomata, Minoru ; Kuse, Naoyuki ; Tone, Mari ; Takada, Kohei ; Muto, Yutaka ; Fujimoto, Kazushi ; Kimura, Hitomi ; Miyamoto, Shingo ; Igarashi, Ataru ; Kunitoh, Hideo</creatorcontrib><description>Abstract
Objectives
Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there are scant data on actual costs and cost-effectiveness in the real world. The aim was to assess the medical costs and outcomes of patients with advanced lung cancer.
Methods
We retrospectively investigated all patients who were diagnosed with advanced lung cancer at the Japanese Red Cross Medical Center between 1 January 2008 and 31 December 2018. Patients were classified into three cohorts according to the year of diagnosis—Cohort 1: 2008–2010, Cohort 2: 2011–2014 and Cohort 3: 2015–2018—and assessed for medical costs and outcome. Medical costs were divided into outpatient and inpatient costs and were calculated on a monthly basis.
Results
Ninety-five patients with small cell lung cancer (SCLC) and 330 with nonsmall cell lung cancer (NSCLC) were included. There was a trend toward increased costs during the first two years after diagnosis in NSCLC patients, without changes in monthly costs, reflecting improved survival. Compared to Cohort 1, Cohort 3 patients with NSCLC had longer survival (median: 24 versus 12 months, P < 0.001), with a median incremental cost of Japanese Yen 6 million during the initial two years. The proportion of outpatient costs increased over time, especially for NSCLC patients (P < 0.001). No changes in costs or survival were observed in SCLC patients.
Conclusions
In NSCLC patients, medical costs increased with prolonged survival during the last decade. The costs on a monthly basis did not change. The proportion of outpatient costs increased.
There was no change in medical costs or survival rates for SCLC. In contrast, medical costs for the first two years after diagnosis increased and the prognosis improved for NSCLC.</description><identifier>ISSN: 1465-3621</identifier><identifier>EISSN: 1465-3621</identifier><identifier>DOI: 10.1093/jjco/hyaa258</identifier><identifier>PMID: 33506249</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Aged ; Aged, 80 and over ; Carcinoma, Non-Small-Cell Lung - economics ; Cohort Studies ; Cost-Benefit Analysis - methods ; Female ; Health Care Costs - standards ; Humans ; Japan ; Lung Neoplasms - economics ; Male ; Middle Aged ; Retrospective Studies ; Time Factors</subject><ispartof>Japanese journal of clinical oncology, 2021-05, Vol.51 (5), p.778-785</ispartof><rights>The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com 2021</rights><rights>The Author(s) 2021. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permission@oup.com.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-280225b8a958976968e231ecaf50f5f87d71622db1ac721a77d1cf359110f3393</citedby><cites>FETCH-LOGICAL-c451t-280225b8a958976968e231ecaf50f5f87d71622db1ac721a77d1cf359110f3393</cites><orcidid>0000-0002-1438-4880</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,1578,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33506249$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Awano, Nobuyasu</creatorcontrib><creatorcontrib>Izumo, Takehiro</creatorcontrib><creatorcontrib>Inomata, Minoru</creatorcontrib><creatorcontrib>Kuse, Naoyuki</creatorcontrib><creatorcontrib>Tone, Mari</creatorcontrib><creatorcontrib>Takada, Kohei</creatorcontrib><creatorcontrib>Muto, Yutaka</creatorcontrib><creatorcontrib>Fujimoto, Kazushi</creatorcontrib><creatorcontrib>Kimura, Hitomi</creatorcontrib><creatorcontrib>Miyamoto, Shingo</creatorcontrib><creatorcontrib>Igarashi, Ataru</creatorcontrib><creatorcontrib>Kunitoh, Hideo</creatorcontrib><title>Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis</title><title>Japanese journal of clinical oncology</title><addtitle>Jpn J Clin Oncol</addtitle><description>Abstract
Objectives
Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there are scant data on actual costs and cost-effectiveness in the real world. The aim was to assess the medical costs and outcomes of patients with advanced lung cancer.
Methods
We retrospectively investigated all patients who were diagnosed with advanced lung cancer at the Japanese Red Cross Medical Center between 1 January 2008 and 31 December 2018. Patients were classified into three cohorts according to the year of diagnosis—Cohort 1: 2008–2010, Cohort 2: 2011–2014 and Cohort 3: 2015–2018—and assessed for medical costs and outcome. Medical costs were divided into outpatient and inpatient costs and were calculated on a monthly basis.
Results
Ninety-five patients with small cell lung cancer (SCLC) and 330 with nonsmall cell lung cancer (NSCLC) were included. There was a trend toward increased costs during the first two years after diagnosis in NSCLC patients, without changes in monthly costs, reflecting improved survival. Compared to Cohort 1, Cohort 3 patients with NSCLC had longer survival (median: 24 versus 12 months, P < 0.001), with a median incremental cost of Japanese Yen 6 million during the initial two years. The proportion of outpatient costs increased over time, especially for NSCLC patients (P < 0.001). No changes in costs or survival were observed in SCLC patients.
Conclusions
In NSCLC patients, medical costs increased with prolonged survival during the last decade. The costs on a monthly basis did not change. The proportion of outpatient costs increased.
There was no change in medical costs or survival rates for SCLC. In contrast, medical costs for the first two years after diagnosis increased and the prognosis improved for NSCLC.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Carcinoma, Non-Small-Cell Lung - economics</subject><subject>Cohort Studies</subject><subject>Cost-Benefit Analysis - methods</subject><subject>Female</subject><subject>Health Care Costs - standards</subject><subject>Humans</subject><subject>Japan</subject><subject>Lung Neoplasms - economics</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Time Factors</subject><issn>1465-3621</issn><issn>1465-3621</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kLtOwzAUQC0EolDYmJE3GAj1I3acEVU8VcQCc-T60bpK7WA7Qv17UrUgJqZ7pXvuGQ4AFxjdYlTTyWqlwmS5kZIwcQBOcMlZQTnBh3_2EThNaYUQYqKsjsGIUoY4KesToF-Ndkq2UIWUEwwWtr1fQCW9MnEY0UDn4YvspIe6j2645aWB1sWUYfAGhgjzV4AbI2OC0ubhy3mX3aDUTi58SC6dgSMr22TO93MMPh7u36dPxezt8Xl6NytUyXAuiECEsLmQNRN1xWsuDKHYKGkZssyKSleYE6LnWKqKYFlVGitLWY0xspTWdAyud94uhs_epNysXVKmbaU3oU8NKQXhnNZ8i97sUBVDStHYpotuLeOmwajZdm22XZt91wG_3Jv7-droX_gn5ABc7YDQd_-rvgERRIHr</recordid><startdate>20210501</startdate><enddate>20210501</enddate><creator>Awano, Nobuyasu</creator><creator>Izumo, Takehiro</creator><creator>Inomata, Minoru</creator><creator>Kuse, Naoyuki</creator><creator>Tone, Mari</creator><creator>Takada, Kohei</creator><creator>Muto, Yutaka</creator><creator>Fujimoto, Kazushi</creator><creator>Kimura, Hitomi</creator><creator>Miyamoto, Shingo</creator><creator>Igarashi, Ataru</creator><creator>Kunitoh, Hideo</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1438-4880</orcidid></search><sort><creationdate>20210501</creationdate><title>Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis</title><author>Awano, Nobuyasu ; Izumo, Takehiro ; Inomata, Minoru ; Kuse, Naoyuki ; Tone, Mari ; Takada, Kohei ; Muto, Yutaka ; Fujimoto, Kazushi ; Kimura, Hitomi ; Miyamoto, Shingo ; Igarashi, Ataru ; Kunitoh, Hideo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-280225b8a958976968e231ecaf50f5f87d71622db1ac721a77d1cf359110f3393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Carcinoma, Non-Small-Cell Lung - economics</topic><topic>Cohort Studies</topic><topic>Cost-Benefit Analysis - methods</topic><topic>Female</topic><topic>Health Care Costs - standards</topic><topic>Humans</topic><topic>Japan</topic><topic>Lung Neoplasms - economics</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Awano, Nobuyasu</creatorcontrib><creatorcontrib>Izumo, Takehiro</creatorcontrib><creatorcontrib>Inomata, Minoru</creatorcontrib><creatorcontrib>Kuse, Naoyuki</creatorcontrib><creatorcontrib>Tone, Mari</creatorcontrib><creatorcontrib>Takada, Kohei</creatorcontrib><creatorcontrib>Muto, Yutaka</creatorcontrib><creatorcontrib>Fujimoto, Kazushi</creatorcontrib><creatorcontrib>Kimura, Hitomi</creatorcontrib><creatorcontrib>Miyamoto, Shingo</creatorcontrib><creatorcontrib>Igarashi, Ataru</creatorcontrib><creatorcontrib>Kunitoh, Hideo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Japanese journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Awano, Nobuyasu</au><au>Izumo, Takehiro</au><au>Inomata, Minoru</au><au>Kuse, Naoyuki</au><au>Tone, Mari</au><au>Takada, Kohei</au><au>Muto, Yutaka</au><au>Fujimoto, Kazushi</au><au>Kimura, Hitomi</au><au>Miyamoto, Shingo</au><au>Igarashi, Ataru</au><au>Kunitoh, Hideo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis</atitle><jtitle>Japanese journal of clinical oncology</jtitle><addtitle>Jpn J Clin Oncol</addtitle><date>2021-05-01</date><risdate>2021</risdate><volume>51</volume><issue>5</issue><spage>778</spage><epage>785</epage><pages>778-785</pages><issn>1465-3621</issn><eissn>1465-3621</eissn><abstract>Abstract
Objectives
Japan’s healthcare expenditures, especially on oncology, are rapidly growing; however, there are scant data on actual costs and cost-effectiveness in the real world. The aim was to assess the medical costs and outcomes of patients with advanced lung cancer.
Methods
We retrospectively investigated all patients who were diagnosed with advanced lung cancer at the Japanese Red Cross Medical Center between 1 January 2008 and 31 December 2018. Patients were classified into three cohorts according to the year of diagnosis—Cohort 1: 2008–2010, Cohort 2: 2011–2014 and Cohort 3: 2015–2018—and assessed for medical costs and outcome. Medical costs were divided into outpatient and inpatient costs and were calculated on a monthly basis.
Results
Ninety-five patients with small cell lung cancer (SCLC) and 330 with nonsmall cell lung cancer (NSCLC) were included. There was a trend toward increased costs during the first two years after diagnosis in NSCLC patients, without changes in monthly costs, reflecting improved survival. Compared to Cohort 1, Cohort 3 patients with NSCLC had longer survival (median: 24 versus 12 months, P < 0.001), with a median incremental cost of Japanese Yen 6 million during the initial two years. The proportion of outpatient costs increased over time, especially for NSCLC patients (P < 0.001). No changes in costs or survival were observed in SCLC patients.
Conclusions
In NSCLC patients, medical costs increased with prolonged survival during the last decade. The costs on a monthly basis did not change. The proportion of outpatient costs increased.
There was no change in medical costs or survival rates for SCLC. In contrast, medical costs for the first two years after diagnosis increased and the prognosis improved for NSCLC.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>33506249</pmid><doi>10.1093/jjco/hyaa258</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-1438-4880</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1465-3621 |
| ispartof | Japanese journal of clinical oncology, 2021-05, Vol.51 (5), p.778-785 |
| issn | 1465-3621 1465-3621 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2482663969 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Aged, 80 and over Carcinoma, Non-Small-Cell Lung - economics Cohort Studies Cost-Benefit Analysis - methods Female Health Care Costs - standards Humans Japan Lung Neoplasms - economics Male Middle Aged Retrospective Studies Time Factors |
| title | Medical costs of lung cancer care in Japan during the first one or two years after initial diagnosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T22%3A11%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Medical%20costs%20of%20lung%20cancer%20care%20in%20Japan%20during%20the%20first%20one%20or%20two%20years%20after%20initial%20diagnosis&rft.jtitle=Japanese%20journal%20of%20clinical%20oncology&rft.au=Awano,%20Nobuyasu&rft.date=2021-05-01&rft.volume=51&rft.issue=5&rft.spage=778&rft.epage=785&rft.pages=778-785&rft.issn=1465-3621&rft.eissn=1465-3621&rft_id=info:doi/10.1093/jjco/hyaa258&rft_dat=%3Cproquest_cross%3E2482663969%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2482663969&rft_id=info:pmid/33506249&rft_oup_id=10.1093/jjco/hyaa258&rfr_iscdi=true |